Drug
Azithromycin 250 mg
Azithromycin 250 mg is a pharmaceutical drug with 5 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
1(20%)
Results Posted
33%(1 trials)
Phase Distribution
Ph phase_3
2
40%
Ph phase_4
1
20%
Ph phase_2
1
20%
Ph phase_1
1
20%
Phase Distribution
1
Early Stage
1
Mid Stage
3
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
2(40.0%)
Phase 4Post-market surveillance
1(20.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(1)
Completed(3)
Other(1)
Detailed Status
Completed3
unknown1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (20.0%)
Phase 21 (20.0%)
Phase 32 (40.0%)
Phase 41 (20.0%)
Trials by Status
unknown120%
completed360%
recruiting120%
Recent Activity
1 active trials
Showing 5 of 5
recruitingphase_3
CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections
NCT03236987
completedphase_2
Azithromycin as Host-directed Therapy for Pulmonary Tuberculosis
NCT03160638
unknownphase_3
Hydroxychloroquine, Azithromycin in the Treatment of Covid-19
NCT04405921
completedphase_1
A Single and Repeat Dose PK/PD Study to Characterise Biomarker Response in Healthy Subjects Treated With Azithromycin
NCT01416350
completedphase_4
AZISAST Study: AZIthromycin in Severe ASThma Study
NCT00760838
Clinical Trials (5)
Showing 5 of 5 trials
NCT03236987Phase 3
CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections
NCT03160638Phase 2
Azithromycin as Host-directed Therapy for Pulmonary Tuberculosis
NCT04405921Phase 3
Hydroxychloroquine, Azithromycin in the Treatment of Covid-19
NCT01416350Phase 1
A Single and Repeat Dose PK/PD Study to Characterise Biomarker Response in Healthy Subjects Treated With Azithromycin
NCT00760838Phase 4
AZISAST Study: AZIthromycin in Severe ASThma Study
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5